| Market Cap | 462.77M | P/E | - | EPS this Y | 12.70% | Ern Qtrly Grth | - |
| Income | -202.11M | Forward P/E | -3.15 | EPS next Y | 17.40% | 50D Avg Chg | -22.00% |
| Sales | 3.64M | PEG | -0.04 | EPS past 5Y | - | 200D Avg Chg | -19.00% |
| Dividend | N/A | Price/Book | 4.07 | EPS next 5Y | 54.70% | 52W High Chg | -50.00% |
| Recommedations | 2.00 | Quick Ratio | 11.21 | Shares Outstanding | 361.49M | 52W Low Chg | 11.00% |
| Insider Own | 1.15% | ROA | -35.69% | Shares Float | 182.14M | Beta | 1.29 |
| Inst Own | 79.24% | ROE | -94.81% | Shares Shorted/Prior | 26.63M/24.53M | Price | 1.89 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 2,655,380 | Target Price | 6.20 |
| Oper. Margin | -3,360.90% | Earnings Date | Nov 6 | Volume | 1,578,230 | Change | -2.58% |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| COATS LONNEL | Chief Executive Offi.. Chief Executive Officer | Nov 10 | Buy | 1.01 | 10,000 | 10,100 | 824,359 | 11/13/23 |
| WADE JEFFREY L | President and CFO President and CFO | Sep 14 | Buy | 1.38 | 10,000 | 13,800 | 264,341 | 09/14/23 |
| Invus US Partners LLC | Director Director | Aug 05 | Buy | 2.50 | 147,390 | 368,475 | 5,451,204 | 08/09/22 |
| Artal International S.C.A. | Director Director | Aug 05 | Buy | 2.50 | 2,426,070 | 6,065,175 | 50,859,331 | 08/09/22 |